

Towards making biologic drugs on demand

J. Christopher Love, Department of Chemical Engineering, The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA

The current timeline for manufacturing high-quality biologic medicines and delivering them to patients typically requires many months. There are many circumstances, however, where the rapid production, release, and delivery of these drugs could address unmet medical needs, including drug shortages, emergency situations, and pandemics. This talk will present a new platform developed to produce biologic medicines on demand called Integrated and Scalable Cyto-Technology (InSCyT). This platform comprises an integrated, subliter-scale portable system for the (semi)continuous operation of fermentation, filtration of cell debris from secreted product, innovative affinity-based purification, polishing, and finishing. This program also emphasizes integrated on-line PAT and process control for QbD production and product qualification for release. Examples of the underlying technologies enabling this platform will be presented, along with a demonstration of the integrated operation to produce high-quality protein therapeutics in less than 48 hours.

Beyond the applications for rapid manufacturing of biologics at point-of-care, the speed of production enabled by automation and integration highlights other opportunities for drug development and conventional manufacturing. These include modeling complete manufacturing processes during process development, rapidly creating materials for preclinical and early-stage clinical testing, and manufacturing therapies for orphan diseases, among others.